Benzinga | Sep 17, 2021 06:51AM EDT

ANI Pharma Reports Launch Of Nebivolol Tablets

-- Current annual market for reference listed drug ("RLD") Bystolic(r) totals more than $1 billion --

-- Simultaneous launch from two manufacturing sites --

BAUDETTE, Minn.--(BUSINESS WIRE)-- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced the launch of Nebivolol Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg.

ANI's Nebivolol Tablets is the generic version of the reference listed drug ("RLD") Bystolic(r). The current annual U.S. market for Bystolic 2.5 mg, 5 mg, 10 mg, and 20 mg strengths is approximately $1.05 billion, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.

"The launch of Nebivolol Tablets highlights our research and development capabilities. On day one, we simultaneously launched across two manufacturing sites, including our site in Baudette, Minnesota, thus showcasing our ability to secure the supply chain for patients and customers," stated Nikhil Lalwani, President and CEO of ANI Pharmaceuticals, Inc.